Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy
about
Myeloid cell signatures in tumor microenvironment predicts therapeutic response in cancerSunitinib: the antiangiogenic effects and beyondPro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic TargetsA clinical and biological perspective of human myeloid-derived suppressor cells in cancer.Unleashing the immune response against childhood solid cancers.Modulating Both Tumor Cell Death and Innate Immunity Is Essential for Improving Radiation Therapy Effectiveness.GM-CSF signalling blockade and chemotherapeutic agents act in concert to inhibit the function of myeloid-derived suppressor cells in vitro.The clinical and prognostic significance of CD14(+)HLA-DR(-/low) myeloid-derived suppressor cells in hepatocellular carcinoma patients receiving radiotherapy.Effects of combined sunitinib and extracranial stereotactic radiotherapy on bone marrow hematopoiesisEndostatin reverses immunosuppression of the tumor microenvironment in lung carcinoma.Janus-Faced Myeloid-Derived Suppressor Cell Exosomes for the Good and the Bad in Cancer and Autoimmune Disease.Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells.Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression.Prognostic role of pretreatment circulating MDSCs in patients with solid malignancies: A meta-analysis of 40 studiesTranslational Potential of Therapeutics Targeting Regulatory Myeloid Cells in Tuberculosis
P2860
Q26752838-F4A2EB7E-5142-4064-ADA6-59C589C8CD6FQ28066499-638660C6-37D9-4612-A53A-F2FAC056B8DAQ28076161-90BC3968-1FBD-49C5-ACF2-07E862BAF7A3Q38847251-8E9F0D2B-E02D-4316-B335-4E1980CECC7AQ39224315-889DB644-1226-4A43-86BD-56902ED886D4Q39365749-49E63B94-F1EE-4F28-8D9D-9896B5A12199Q40032613-6055CBD0-05FE-4C6E-98BF-823384AD21ADQ40929576-CDA60266-9786-45D9-ADA6-951E69B15483Q41150956-E8956199-147B-41BB-A3B9-25DC626A238AQ49622371-5BEA63A4-F30A-4568-9B16-A26FF9AF7AFFQ49884887-77BB5920-D72F-4DA1-86A7-42D752BCAC5AQ50426810-52948631-3FDF-4924-9A46-48C5CDAD22A3Q55265921-C6403C7E-13B5-454E-B188-45E2C9608FD9Q57138311-3221292A-36CD-4CE0-ABA9-D2A943F5B32DQ57299995-D1D16F60-D110-4CA8-8B09-57DB35ACABD2
P2860
Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Myeloid-Derived Suppressor Cel ...... Stereotactic Body Radiotherapy
@ast
Myeloid-Derived Suppressor Cel ...... Stereotactic Body Radiotherapy
@en
type
label
Myeloid-Derived Suppressor Cel ...... Stereotactic Body Radiotherapy
@ast
Myeloid-Derived Suppressor Cel ...... Stereotactic Body Radiotherapy
@en
prefLabel
Myeloid-Derived Suppressor Cel ...... Stereotactic Body Radiotherapy
@ast
Myeloid-Derived Suppressor Cel ...... Stereotactic Body Radiotherapy
@en
P2093
P2860
P1476
Myeloid-Derived Suppressor Cel ...... Stereotactic Body Radiotherapy
@en
P2093
Brian A Coakley
Celia Divino
Hui-Ming Chen
John Mandeli
Johnny Kao
Junko Ozao
Lu-Hai Wang
Myron Schwartz
P2860
P304
P356
10.1158/1078-0432.CCR-14-2742
P407
P50
P577
2015-04-28T00:00:00Z